Tamoxifen

Generic Name: Tamoxifen

Brand Names: Soltamox

Drug Type: Small Molecule

Chemical Formula: C_₂₆H_₂₉NO

CAS Number: 10540-29-1

Unique Ingredient Identifier: 094ZI81Y45

Background: Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations. Tamoxifen is used alone or as an adjuvant in these treatments. Tamoxifen may no longer be the preferred treatment for these types of cancers as patients generally have better survival, side effect profiles, and compliance with anastrozole.

Tamoxifen was granted FDA approval on 30 December 1977.

Indication: Tamoxifen is indicated to treat estrogen receptor positive metastatic breast cancer in adults, as an adjuvant in the treatment of early stage estrogen receptor positive breast cancer in adults, to reduce the risk of invasive breast cancer after surgery and radiation in adult women with ductal carcinoma in situ.

Associated Conditions: Breast Cancer, Contralateral Breast Cancer, Desmoid Tumor, Early Stage Estrogen Receptor (ER) Positive Breast Cancer, Gynecomastia, Invasive Breast Cancer, Ovarian Cancer, Puberty, Precocious, Metastatic Estrogen Receptor Positive Breast Cancer

Associated Therapies: Ovulation induction therapy

Clinical Trials

Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors

Phase 2

Completed

Conditions: Adrenocortical Carcinoma
Brain and Central Nervous System Tumors
Head and Neck Cancer
Liver Cancer
Malignant Mesothelioma
Pheochromocytoma
Sarcoma

First Posted Date: 2003-01-27

Last Posted Date: 2013-07-10

Lead Sponsor: Ottawa Regional Cancer Centre

Target Recruit Count: 30

Registration Number: NCT00002608

Locations: 🇨🇦
Ottawa Regional Cancer Centre at Ottawa Hospital - General Campus, Ottawa, Ontario, Canada

Tamoxifen in Treating Women With Breast Cancer

Phase 3

Conditions: Breast Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-12-19

Lead Sponsor: University Hospital Birmingham

Target Recruit Count: 20000

Registration Number: NCT00003678

Locations: 🇬🇧
Cancer Research UK Clinical Trials Unit - Birmingham, Birmingham, England, United Kingdom

SU5416 and Doxorubicin in Treating Patients With Stage IIIB or Stage IV Inflammatory Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2010-06-11

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 21

Registration Number: NCT00005822

Locations: 🇺🇸
Ireland Cancer Center at University Hospitals Case Medical Center, Cleveland, Ohio, United States

Tipifarnib Plus Tamoxifen in Treating Women With Metastatic Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-06-19

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00052728

Locations: 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
🇺🇸
NCI - Center for Cancer Research, Bethesda, Maryland, United States

Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer

Phase 3

Completed

Conditions: Breast Adenocarcinoma
Stage IA Breast Cancer AJCC v7
Stage IIB Breast Cancer AJCC v6 and v7
Stage IIIA Breast Cancer AJCC v7
HER2 Positive Breast Carcinoma
Stage IB Breast Cancer AJCC v7
Stage IIA Breast Cancer AJCC v6 and v7

Interventions: Drug: Aromatase Inhibition Therapy
Drug: Cyclophosphamide
Drug: Doxorubicin Hydrochloride
Other: Laboratory Biomarker Analysis
Drug: Paclitaxel
Drug: Tamoxifen Citrate
Biological: Trastuzumab

First Posted Date: 2003-01-27

Last Posted Date: 2020-08-14

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 3436

Registration Number: NCT00005970

Locations: 🇺🇸
University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸
University of Vermont and State Agricultural College, Burlington, Vermont, United States

and more 154 locations

Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer

Phase 2

Completed

Conditions: Estrogen Receptor-negative Breast Cancer
Male Breast Cancer
Estrogen Receptor-positive Breast Cancer
Progesterone Receptor-negative Breast Cancer
Inflammatory Breast Cancer
Progesterone Receptor-positive Breast Cancer
Stage IIIB Breast Cancer
Stage IV Breast Cancer

Interventions: Drug: tamoxifen citrate
Drug: busulfan
Drug: thiotepa
Drug: melphalan
Biological: aldesleukin
Biological: sargramostim
Procedure: peripheral blood stem cell transplantation
Radiation: radiation therapy

First Posted Date: 2003-01-27

Last Posted Date: 2017-07-12

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 50

Registration Number: NCT00003199

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/Puget Sound Oncology Consortium, Seattle, Washington, United States

Surgery With or Without Lymph Node Removal in Treating Older Women With Stage I Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-09-20

Lead Sponsor: European Institute of Oncology

Target Recruit Count: 642

Registration Number: NCT00002720

Locations: 🇮🇹
Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano (Milan), Italy

Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-08-02

Lead Sponsor: Cancer Research Campaign Clinical Trials Centre

Target Recruit Count: 4400

Registration Number: NCT00032136

Locations: 🇬🇧
City Hospital - Birmingham, Birmingham, England, United Kingdom

Chemotherapy Plus Surgery in Treating Women With Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-09-17

Lead Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Target Recruit Count: 450

Registration Number: NCT00003013

Locations: 🇦🇹
Kaiser Franz Josef Hospital, Vienna, Austria
🇨🇿
Radiotherapy Institute, Ostrava-Poruba, Czech Republic
🇸🇰
St. Elizabeth Cancer Institute Hospital, Bratislava, Slovakia

and more 25 locations

Adjuvant Stage 2-3A Breast Cancer With Positive Lymph Nodes

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Biological: filgrastim
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: paclitaxel
Drug: tamoxifen citrate
Procedure: adjuvant therapy
Radiation: radiation therapy

First Posted Date: 2003-01-27

Last Posted Date: 2012-10-02

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 16

Registration Number: NCT00007904

Locations: 🇺🇸
Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
🇺🇸
UH-LUICC, Mentor, Ohio, United States
🇺🇸
UH-Chagrin Highlands, Orange Village, Ohio, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy